CMS

Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Fierce Pharma
Eisai
Leqembi
FDA
CMS
Alzheimer's disease
Flag link:
Alzheimer's Association campaigns for broader Leqembi coverage: report
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
CMS lays out plans for negotiating drug prices
CMS lays out plans for negotiating drug prices
BioPharma Dive
CMS
Medicare
drug pricing
Flag link:
8 Moments that Defined Diabetes Tech
8 Moments that Defined Diabetes Tech
Medical Devices and Diagnostics Industry
diabetes
Medtech
Medtronic
Sensionics
Verily
Embecta
DexCom
Apple
CMS
Abbott Labs
Flag link:
Medicare maintains limits on Eisai’s new Alzheimer’s drug
Medicare maintains limits on Eisai’s new Alzheimer’s drug
BioPharma Dive
Medicare
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Flag link:
CMS Outlines 3 New Drug Pricing Models Targeting Wide Scope of Therapies
CMS Outlines 3 New Drug Pricing Models Targeting Wide Scope of Therapies
American Journal of Managed Care
drug pricing
CMS
Medicare
Medicaid
accelerated approval
Flag link:
CMS needs to strengthen its internal controls to ensure Part B drug payment accuracy, OIG finds
CMS needs to strengthen its internal controls to ensure Part B drug payment accuracy, OIG finds
Endpoints
CMS
Medicare
Medicare Part B
Flag link:
Ahead of lecanemab decision, Alzheimer's groups petition CMS to reverse coverage policy
Ahead of lecanemab decision, Alzheimer's groups petition CMS to reverse coverage policy
Endpoints
Biogen
FDA
Alzheimer's disease
CMS
clinical trials
Flag link:
US govt addressing Medicare payments for biosimilars
US govt addressing Medicare payments for biosimilars
Pharma Letter
HHS
Medicare
biosimilars
Medicare Part B
Inflation Reduction Act
CMS
Flag link:
Stryker Is Smart to Pursue This Type of Reimbursement
Stryker Is Smart to Pursue This Type of Reimbursement
Medical Devices and Diagnostics Industry
Medtech
devices
reimbursement
Skryker
InSpace balloon implants
outpatient hospitals
CMS
Flag link:
Survey puts spotlight on US neurologists’ response to CMS Alzheimer drugs decision
Survey puts spotlight on US neurologists’ response to CMS Alzheimer drugs decision
Biopharma Reporter
Biogen
Aduhelm
monoclonal antibodies
CMS
Alzheimer's disease
neurologists
Flag link:
Is Biogen Planning to Appeal CMS Aduhelm Reimbursement Decision?
Is Biogen Planning to Appeal CMS Aduhelm Reimbursement Decision?
BioSpace
Biogen
CMS
Alzheimer's disease
Aduhelm
Flag link:
The next battle in the never-ending war over Aduhelm
The next battle in the never-ending war over Aduhelm
Stat
Biogen
Aduhelm
Medicare
CMS
Eli Lilly
Alzheimer's disease
Flag link:
CMS official on Alzheimer's drug coverage decision: Don't read between the lines for other accelerated approvals
CMS official on Alzheimer's drug coverage decision: Don't read between the lines for other accelerated approvals
Endpoints
CMS
Medicare
Biogen
Aduhelm
accelerated approvals
Flag link:
How CMS independence is at the forefront of its Alzheimer's drug coverage decision
How CMS independence is at the forefront of its Alzheimer's drug coverage decision
Endpoints
CMS
Medicare
Biogen
Aduhelm
Alzheimer's disease
Flag link:
CMS finalizes restrictions on Biogen's Alzheimer's drug coverage, will only fund use in clinical trials
CMS finalizes restrictions on Biogen's Alzheimer's drug coverage, will only fund use in clinical trials
Endpoints
Biogen
Aduhelm
CMS
Alzheimer's disease
clinical trials
Medicare
Flag link:
More biosimilar use could've saved Medicare and beneficiaries $84M in 2019, HHS OIG says
More biosimilar use could've saved Medicare and beneficiaries $84M in 2019, HHS OIG says
Endpoints
biosimilars
Medicare
CMS
Medicare Part D
Flag link:
Eli Lilly and Roche ask CMS not to be lumped in with Aduhelm’s restrictive judgment
Eli Lilly and Roche ask CMS not to be lumped in with Aduhelm’s restrictive judgment
Endpoints
Eli Lilly
Roche
Biogen
Alzheimer's disease
Aduhelm
CMS
Flag link:
Eisai bites back against restricted coverage plan for Aduhelm
Eisai bites back against restricted coverage plan for Aduhelm
Pharmaforum
Eisai
Biogen
Aduhelm
Alzheimer's disease
FDA
CMS
Flag link:
Backing Biogen, 75+ House Republicans call on CMS to abandon its decision to limit amyloid-targeted Alzheimer's drugs to trials
Backing Biogen, 75+ House Republicans call on CMS to abandon its decision to limit amyloid-targeted Alzheimer's drugs to trials
Endpoints
Biogen
Aduhelm
CMS
Alzheimer's disease
Flag link:

Pages